Literature DB >> 11303053

Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.

S K Paulson1, M B Vaughn, S M Jessen, Y Lawal, C J Gresk, B Yan, T J Maziasz, C S Cook, A Karim.   

Abstract

Celecoxib pharmacokinetics was evaluated after single and multiple oral dosing; after dosing in a solution and as a solid; with and without food; and after administration into different sites of the GI tract using dog. After oral dosing in a solution, celecoxib was rapidly absorbed and reached maximum concentrations by 1 h; absorption was delayed another 1 to 2 h when administered as a solid. The absolute bioavailability of celecoxib was higher when given as a solution (64--88%) compared with capsule (22--40%). The absorption of celecoxib given in a capsule was delayed by food, although systemic exposure increased by 3- to 5-fold. The systemic availability of celecoxib given intragastrically in solution was similar to that obtained following direct instillation into the duodenum, jejunum, or colon through a chronic intestinal access port. Collectively, these data suggest that celecoxib is a highly permeable drug that can be absorbed throughout the GI tract and that dissolution may be a rate-limiting factor for absorption from solid dosage forms. Unlike dogs, celecoxib given to humans with a high fat meal exhibits only a slight increase in AUC(0--infinity) (11%) that is not clinically significant with regard to safety or efficacy. In humans, a lower dose and a longer GI residence time may promote the opportunity for absorption of a poorly soluble drug such as celecoxib that can be absorbed throughout the GI tract. This would minimize the effect of food on absorption; as such, patients with arthritis can be given celecoxib with or without food.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303053

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  50 in total

1.  Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration.

Authors:  Jing Li; Hung Huynh; Eli Chan
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

2.  Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

Authors:  C Skarke; N Alamuddin; J A Lawson; L Cen; K J Propert; G A Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  2012-01-25       Impact factor: 6.875

3.  Design and evaluation of celecoxib porous particles using melt sonocrystallization.

Authors:  Anant Paradkar; Manish Maheshwari; Ravindra Kamble; Ian Grimsey; Peter York
Journal:  Pharm Res       Date:  2006-06-07       Impact factor: 4.200

4.  Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Authors:  Hannah M Jones; Neil Parrott; Gerd Ohlenbusch; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Predicting effect of food on extent of drug absorption based on physicochemical properties.

Authors:  Chong-Hui Gu; Hua Li; Jaquan Levons; Kimberley Lentz; Rajesh B Gandhi; Krishnaswamy Raghavan; Ronald L Smith
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.200

6.  Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.

Authors:  Mark Stroh; Carol Addy; Yunhui Wu; S Aubrey Stoch; Nazaneen Pourkavoos; Michelle Groff; Yang Xu; John Wagner; Keith Gottesdiener; Craig Shadle; Hong Wang; Kimberly Manser; Gregory A Winchell; Julie A Stone
Journal:  AAPS J       Date:  2009-02-06       Impact factor: 4.009

Review 7.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

8.  A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib.

Authors:  Yanzhuo Zhang; Hong Wang; Chuanjun Li; Baoxiang Sun; Yu Wang; Siling Wang; Cunqiang Gao
Journal:  Pharm Res       Date:  2013-11-28       Impact factor: 4.200

9.  Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys.

Authors:  Min-Jeong Kim; Stal S Shrestha; Michelle Cortes; Prachi Singh; Cheryl Morse; Jeih-San Liow; Robert L Gladding; Chad Brouwer; Katharine Henry; Evan Gallagher; George L Tye; Sami S Zoghbi; Masahiro Fujita; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2018-06-29       Impact factor: 10.057

Review 10.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.